CRBU — Caribou Biosciences, Inc.
$0.5328-4.86%
Last close: · regular session
After-hours $0.5306 -0.41% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for CRBU in the TickerWise workspace.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 147
- Website: https://cariboubio.com
Latest SEC filings for CRBU
Latest CRBU news
- Caribou falls as analysts downgrade on plans to explore strategic alternatives Read article
- Caribou Biosciences to halt CAR-T programs, explore strategic alternatives Read article
- Caribou Biosciences to Evaluate Strategic Alternatives Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.